DAY ONE: Stream B: Stem Cells for Drug Discovery

last modified: 22 May '12

Please enable javascript to see more information on speakers

2.30pm

Chairman’s opening remarks

Prof John Rasko

Professor Rasko is an Australian pioneer in the application of adult stem cells and genetic therapy. He directs the Department of Cell and Molecular Therapies at Royal Prince Alfred Hospital and heads the Gene and Stem Cell Therapy Program at the...

more..

› Prof John Rasko, Director, Department of Cell & Molecular Therapies, Royal Prince Alfred Hospital

CURRENT LANDSCAPE OF iPS APPLICATION FOR DRUG DISCOVERY

2.35pm

Evaluating the progress and efficacy of iPS cells in drug discovery

Dr. Nancy Stagliano

Nancy Stagliano, Ph.D. joined iPierian as Chief Executive Officer in September 2011 with an accomplished career as a biotech leader spanning all aspects of the industry, from discovery research and strategy to global medical affairs and corporate...

more..

What is the current state of iPS cell research?
What are the technology’s strengths and weaknesses?
What advancements need to occur for iPS cells to become a viable therapeutic technology?
What are the challenges facing drug discovery using iPS cells going forward?

› Dr. Nancy Stagliano, CEO, iPierian, Inc.

3pm

Drug discovery using disease-specific iPS models

Lee Rubin

Dr. Rubin received his Ph.D. in Neuroscience from The Rockefeller University and completed postdoctoral fellowships in Pharmacology from Harvard Medical School and in Neurobiology from Stanford University School of Medicine. He has worked both in...

more..

What are the challenges of generating iPS cells using a diseased model?
What are the benefits promised?
Should cell types not targeted by drugs be tested for side effects?
Could this be the ultimate in personalised medicine?

› Lee Rubin, Director of Translational Medicine, Harvard Stem Cell Institute

3.25pm

Pharmaceutical Grade iPS Cells: platforms for drug discovery

Peter Flynn

Dr Flynn is the Vice President of Biologic Therapeutics and iPSC technology at Fate Therapeutics. He manages the in vivo protein therapeutics pipeline and preclinical development and the iPSC technology group including the collaboration with Becton...

more..

What is the current state of play for iPSC usage in drug discovery?
What challenges are associated with current iPSC technology?
Platforms for HTP generation and characterization of iPSC
Technologies for improved differentiation efficiencies

› Peter Flynn, VP Biologic Therapeutics, Fate Therapeutics

3.50pm

New predictive in vitro models in drug development: human iPS cells and their derivatives

Chris Parker

Mr. Kendrick-Parker is responsible for sales, marketing and business development. Mr. Kendrick-Parker brings more than 20 years of experience in the life science industry to CDI. As a Vice President at Affymetrix, he managed all aspects of sales and ...

more..

Large-scale production of pure populations of well-characterized terminal cells
Incorporating hIPSCs into the drug discovery and safety tox pipelines
Utility of creating custom hiPSC-derived terminal cell types in disease modeling
What will be the impact of hiPSCs on future cell-based therapies

› Chris Parker, VP & Chief Commercial Officer, Cellular Dynamics International

4.15pm

Afternoon refreshments

4.45pm

New technology approach for high quality & large scale production of hPSCs

Takashi Asada

Dr. Asada (Professor in iCeMS, Kyoto University) is Project Manager of NEDO (New Energy and Industrial Technology Development Organization) Project, which has been started last year for 5 years project for the aim to build a robust system for cell...

more..

Targeting for both cell therapy & drug discovery by open innovation in Japan
New culture system for large scale GMP production for ES/iPS cells
Application for company drug discovery, cardiomyocytes and hepatocytes for in vitro assay

› Takashi Asada, Professor, Kyoto University

5.10pm

IMI call: hiPS cells for drug discovery and safety assessment

Fatiha Sadallah

Fatiha Sadallah is responsible for the IMI collaborative research in the field of Education and Training. She manages the implementation of the Education and Training programme while addressing the scientific priorities of the IMI Call topics. She...

more..

How is the IMI spurring a paradigm shift in drug discovery and safety assessment?
How will this project look to mimic patient responses and enable development of personalised
medicine?
What will be the three main areas of research?
How will this address disease biology and responses to drug treatment for diseases with no available animal models?

› Fatiha Sadallah, Principal Scientific Manager, IMI

EXPLOITING ALL STEM CELL TYPES FOR DRUG DISCOVERY

5.35pm

Panel discussion: understanding the appropriate stem cell type as a platform for your drug discovery protocol

Davide Danovi

Davide had his MD and then PhD at the European Institute of Oncology in Milan, Italy. He then joined the laboratory of Austin Smith at the University of Cambridge, UK where he has taken forward pioneering work of Steve Pollard on brain tumour stem...

more..

Andreas Nuessler

Prof. Andreas K. Nussler is a German native. He studied Pharmacy and human biology in Germany and France. He received his PhD from University Paris VI, France in 1991. From 1991 to 1994 he worked as Research Assistant Prof. at Pittsburgh Medical...

more..

Lee Rubin

more..

Comparing iPS cells, hES cells, and cancer stem cells as effective drug discovery tools
What are the benefits of using these cell types?
How are stem cells incorporated into existing paradigms of drug development?
What is the potential for stem cell-based drug discovery in personalised medicine?